The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M01 | Antiinflammatory and antirheumatic products | |
3
|
M01A | Antiinflammatory and antirheumatic products, non-steroids | |
4
|
M01AC | Oxicams | |
5
|
M01AC05 | Lornoxicam |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 12 mg | |
| PAREN | Parenteral | 12 mg | |
| RECTAL | Rectal | 12 mg |
| Active Ingredient |
|---|
|
Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme) leading to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception, which seems to be independent of anti-inflammatory effects has also been suggested. |
| Document | Type | Information Source | |
|---|---|---|---|
| XEFO Film-coated tablets | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| XEFO Powder and solvent for solution for injection | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.